CF
TVTX icon

Cantor Fitzgerald’s Travere Therapeutics TVTX Stock Holding History

Cantor Fitzgerald’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-50,000
Closed -$1.2M – 374
2025
Q3 		$1.2M Sell
50,000
-25,000
-33% -$470K 0.01% 196
2025
Q2 		$1.11M Buy
75,000
+50,000
+200% +$829K 0.02% 148
2025
Q1 		$448K Buy
+25,000
New +$507K 0.01% 160
2024
Q4 		– Sell
-13,800
Closed -$193K – 339
2024
Q3 		$193K Buy
+13,800
New +$144K 0.01% 141

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Cantor Fitzgerald's TVTX Position: Q4 2024 in Review

Cantor Fitzgerald sold out of Travere Therapeutics (TVTX) in Q4 2024, closing a stake of 35,748 shares — an estimated $500K sold.

Cantor Fitzgerald first reported a position in TVTX in Q3 2024 and held it in 1 quarter. The position peaked at $500K in Q3 2024. 197 funds tracked by Wall St. Rank hold TVTX as of Q4 2024.

  • Cantor Fitzgerald reported no remaining Travere Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Cantor Fitzgerald sold 35,748 Travere Therapeutics shares in Q4 2024, an estimated $500K.
  • Cantor Fitzgerald first reported a position in Travere Therapeutics in Q3 2024 and held it in 1 quarter.
  • Cantor Fitzgerald's Travere Therapeutics position peaked at $500K in Q3 2024.
  • 197 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2024.

Based on Cantor Fitzgerald's 13F filing for Q4 2024, filed 14 Feb 2025.